Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | RNA binding protein | 0.0076 | 0.5948 | 0.5948 |
Entamoeba histolytica | hypothetical protein | 0.0076 | 0.5845 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0076 | 0.5845 | 0.9798 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0035 | 0.0862 | 0.0862 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.5948 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.5948 | 0.5948 |
Brugia malayi | hypothetical protein | 0.0076 | 0.5845 | 0.5845 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5948 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5948 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0076 | 0.5845 | 0.9798 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.5948 | 0.5948 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.5948 | 0.5948 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0035 | 0.0862 | 0.0862 |
Loa Loa (eye worm) | hypothetical protein | 0.0035 | 0.0862 | 0.0862 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0076 | 0.5845 | 0.9798 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.5948 | 0.5948 |
Entamoeba histolytica | hypothetical protein | 0.0076 | 0.5845 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0076 | 0.5845 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5948 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5948 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0076 | 0.5845 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0075 | 0.577 | 0.577 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.5948 | 1 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0035 | 0.0862 | 0.0862 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0075 | 0.577 | 0.577 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.5948 | 0.5948 |
Schistosoma mansoni | hypothetical protein | 0.0075 | 0.577 | 0.9651 |
Schistosoma mansoni | hypothetical protein | 0.0076 | 0.5845 | 0.9798 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.5948 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.5119 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.081 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 56.2341 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen. (Class of assay: confirmatory) [Related pubchem assays: 1473, 1466 ] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.